Gene · 8030
Papers1,913
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 1,913
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. | Mol Cell | 2023 | 36736316 | PubTator, text mining | PubMed |
| Comparison of ultrasonography and pathology features between children and adolescents with papillary thyroid carcinoma. | Heliyon | 2023 | 36704282 | PubTator, text mining | PubMed |
| Targeting Pim kinases in hematological cancers: molecular and clinical review. | Mol Cancer | 2023 | 36694243 | PubTator, text mining | PubMed |
| Genomic landscape of 891 RET fusions detected across diverse solid tumor types. | NPJ Precis Oncol | 2023 | 36690680 | PubTator, text mining | PubMed |
| Phase Separation in Biology and Disease; Current Perspectives and Open Questions. | J Mol Biol | 2023 | 36690068 | PubTator, text mining | PubMed |
| Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces-A Review. | Pharmaceutics | 2023 | 36678867 | PubTator, text mining | PubMed |
| Thyroid Collision Tumors: The Presence of the Medullary Thyroid Carcinoma Component Negatively Influences the Prognosis. | Diagnostics (Basel) | 2023 | 36673095 | PubTator, text mining | PubMed |
| Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib. | J Thorac Oncol | 2023 | 36657661 | PubTator, text mining | PubMed |
| Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. | Cell Rep Med | 2023 | 36657446 | PubTator, text mining | PubMed |
| KRAS inhibition in metastatic colorectal cancer: An update. | Curr Opin Pharmacol | 2023 | 36638742 | PubTator, text mining | PubMed |
| RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives. | Pharmacol Ther | 2023 | 36632846 | PubTator, text mining | PubMed |
| Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China. | Technol Cancer Res Treat | 2023 | 36628459 | PubTator, text mining | PubMed |
| Neoantigens: promising targets for cancer therapy. | Signal Transduct Target Ther | 2023 | 36604431 | PubTator, text mining | PubMed |
| Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan. | Cancer Sci | 2023 | 36601953 | PubTator, text mining | PubMed |
| Human Proteome Microarray identifies autoantibodies to tumor-associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma. | Mol Oncol | 2023 | 36587394 | PubTator, text mining | PubMed |
| Kinase regulation by liquid-liquid phase separation. | Trends Cell Biol | 2023 | 36528418 | PubTator, text mining | PubMed |
| Recent advances in cancer fusion transcript detection. | Brief Bioinform | 2023 | 36527429 | PubTator, text mining | PubMed |
| COVID-19 signalome: Potential therapeutic interventions. | Cell Signal | 2023 | 36521656 | PubTator, text mining | PubMed |
| Adversary of DNA integrity: A long non-coding RNA stimulates driver oncogenic chromosomal rearrangement in human thyroid cells. | Int J Cancer | 2023 | 36510744 | PubTator, text mining | PubMed |
| Reversing "Flip-Flop" Phenomenon of 131 I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory Thyroid Cancer Lesions After Treatment of Pralsetinib. | Clin Nucl Med | 2023 | 36327463 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8030/papers?page=17